The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
Filter by category
- All
- Blog
- Congress
- Scientific resource
- Webinar
- Poster
- Scientific publication
- Press release
- Press coverage
- News
Filter by category
Scientific publication
12/06/2021
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Scientific publication
19/05/2021
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Press release
18/05/2021
InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.
Webinar
04/05/2021
[EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection
Novel approaches in drug discovery using innovative models (PDX & PDX-derived models) to better mimic the situation of the human cancer pathologies.
Scientific publication
22/04/2021
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
Read in Communication Biologics (Nature), the data from the exoSTING preclinical program, in which Oncodesign participated (Hepa1-6).
Poster
20/04/2021
Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1
Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.
Poster
14/04/2021
Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment
In this study we describe establishment of a luminal breast cancer PDX model with acquired resistance to hormonotherapy
Scientific resource
01/04/2021
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Scientific publication
12/02/2021
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection
